Canada’s Drug Agency (CDA-AMC) recommends that Qalsody be reimbursed by public drug plans for the treatment of adults with amyotrophic lateral sclerosis (ALS) if certain conditions are met.
Canada’s Drug Agency (CDA-AMC) recommends that Qalsody be reimbursed by public drug plans for the treatment of adults with amyotrophic lateral sclerosis (ALS) if certain conditions are met.